靶向α治疗[225Ac]Ac-DOTATATE与挽救性[177Lu]Lu-DOTATATE PRRT在进展性转移性NET中的比较
单中心回顾性观察研究纳入40例既往接受4-6周期[177Lu]Lu-DOTATATE后出现进展的转移性神经内分泌肿瘤患者,比较[225Ac]Ac-DOTATATE与挽救性[177Lu]Lu-DOTATATE的疗效与毒性。两臂毒性均以轻度为主,无3级及以上不良事件;TAT组在症状、生化及影像缓解率上数值更高,但PFS与OS差异均未达统计学显著。
要点
- 两臂均无3级及以上不良事件,毒性以轻度可控为主。
- TAT组症状CR 15%、PR 35%,挽救PRRT组无CR、PR 20%。
- TAT组影像ORR 35% vs 挽救PRRT组10%,DCR 80% vs 60%。
核心结论
- [225Ac]Ac-DOTATATE与挽救性[177Lu]Lu-DOTATATE对进展性转移性NET均有效且耐受良好,无高级别毒性。
- TAT在临床、生化及影像缓解率上数值更高,提示α发射体可能部分克服既往β发射体治疗耐药。
- 需前瞻性、更大规模多中心随机试验验证并优化患者选择。
研究设计与样本
- 单中心、回顾性观察性分析,于三级医疗中心开展。
- 纳入既往接受4-6周期[177Lu]Lu-DOTATATE后达客观缓解或稳定、间隔超过6个月后进展并接受后续治疗的转移性NET患者。
- 按实际接受治疗分为A臂[225Ac]Ac-DOTATATE与B臂挽救性[177Lu]Lu-DOTATATE,两臂基线特征匹配。
- 共纳入并分析40例患者,每臂20例。
主要发现
- 症状缓解:A臂CR 3例(15%)、PR 7例(35%),B臂无CR、PR 4例(20%)。
- 血清CgA生化部分改善:A臂10例(50%),B臂5例(25%)。
- 解剖影像DCR:A臂80%,B臂60%;RECIST 1.1的ORR:A臂35%,B臂10%。
- 中位PFS:A臂10个月(95%CI 6.0-24.0),B臂12个月(95%CI 4.0-33.0)。
- 中位OS:A臂16个月(95%CI 10-16),B臂未达到;PFS与OS差异均无统计学意义。
关键数值与推荐
- 疗效评估分症状、生化(血清CgA)及功能与解剖影像三类。
- 影像疗效采用RECIST 1.1标准判定CR、PR、SD、PD,并计算DCR与ORR。
- 毒性两臂均以轻度、可控为主,均无3级及以上不良事件。
临床怎么用
- 对初始[177Lu]Lu-DOTATATE治疗后缓解或稳定、间隔超过6个月后进展的转移性NET,可考虑[225Ac]Ac-DOTATATE或挽救性[177Lu]Lu-DOTATATE。
- 两方案毒性均以轻度为主,选择时可结合放射性核素可及性、患者意愿及经济条件。
- TAT影像与生化缓解率数值更高,但生存获益尚未证实,需个体化决策。
局限性
- 单中心回顾性观察设计,样本量40例,每臂20例。
- 分组取决于核素可及性、患者选择及经济限制,非随机分配。
- PFS与OS差异均未达统计学显著,结论需前瞻性随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate and compare the therapeutic response, progression-free survival (PFS), overall survival (OS), and clinical toxicity of targeted alpha therapy (TAT) [ 225 Ac]Ac-DOTATATE and salvage [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumor (NET) patients who showed an objective response or disease stabilization following an initial course of [ 177 Lu]Lu-DOTATATE PRRT and eventually developed progressive disease after a time interval of more than 6 months. PATIENTS AND METHODS: This was a single-institution, retrospective observational analysis conducted at a tertiary care institute. The medical records of metastatic NET patients who had been previously treated with an initial course of PRRT (I-PRRT) with 4-6 cycles of [ 177 Lu]Lu-DOTATATE and showed an objective response or stable disease (SD) on the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria after I-PRRT, but eventually developed progressive disease (PD) after a time gap of more than 6 months, and subsequently received [ 225 Ac]Ac-DOTATATE or salvage [ 177 Lu]Lu-DOTATATE were analyzed. These patients with matched baseline characteristics (site of primary disease, WHO grading of tumors, Ki-67 index, disease burden, [ 18 F]F-FDG avidity, and previously treatments) were divided into the 2 treatment arms based on the treatment received by them, which in turn depended upon availability of therapeutic radionuclide, patient choice, and financial constraints as follows: Arm A: [ 225 Ac]Ac-DOTATATE and Arm B: salvage [ 177 Lu]Lu-DOTATATE. The treatment response was evaluated under 3 categories for all patients: (a) symptomatic, (b) biochemical, and (c) functional and anatomic imaging response. RESULTS: A total of 40 patients with metastatic NET (20 in each arm) were included and analyzed in the study. On the symptomatic response, 3 (15%) patients demonstrated a complete response (CR), and 7 (35%) patients demonstrated partial response (PR) in arm A, compared with no CR and PR of 4 (20%) patients in arm B. Biochemical response assessed by using serum CgA showed partial improvement in 10 (50%) patients in arm A versus 5 (25%) patients in arm B. On anatomic imaging, the disease control rate (DCR) was found to be 80% in arm A and 60% in arm B. The objective response rate (ORR) calculated based upon RECIST 1.1 criteria was 35% in arm A and 10% in arm B. The median progression-free survival was 10 months (95% CI, 6.0-24.0) in arm A and 12 months (95% CI, 4.0-33.0) in arm B, while the median overall survival was 16 months (95% CI, 10-16) in arm A and was not reached in arm B; neither difference reached statistical significance. Toxicities in both arms were predominantly mild and manageable, with no grade 3 or higher adverse events in either arm. CONCLUSIONS: This observational study shows that [ 225 Ac]Ac-DOTATATE and salvage PRRT with [ 177 Lu]Lu-DOTATATE are both efficacious and well-tolerated treatments for progressive metastatic NETs without high-grade toxicity. The numerically superior clinical, biochemical, and imaging response rates observed with TAT indicate that alpha-emitting radionuclides may partly overcome resistance to prior beta-emitter therapy. Prospective, larger multicenter randomized trials are needed to validate these findings, refine patient selection, and determine the appropriate treatment of alpha- or salvage beta-emitting radionuclide therapies in progressive NETs.
引用
- Agrawal R, Parghane RV, Basu S, et al. Targeted Alpha Therapy With [ 225 Ac]Ac-DOTATATE Versus Salvage Retreatment PRRT With [ 177 Lu]Lu-DOTATATE in Progressive Metastatic Neuroendocrine Tumor Patients After Initial Course of [ 177 Lu]Lu-DOTATATE Treatment : An Observational Study Comparing the Therapeutic Response, Survival, and Clinical Toxicity. Clin Nucl Med. 2026. PMID: 42302403. doi:10.1097/RLU.0000000000006578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。